ABP
Abpro Holdings
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ABP
Abpro Holdings, Inc.
A biotechnology company dedicated to developing the next generation of antibody therapies
68 Cummings Park Drive, Woburn, MA 01801
--
Abpro Holdings, Inc., was incorporated in Delaware on May 20, 2021. The company is a biotechnology company focused on developing next-generation antibody therapies designed to improve the lives of patients with serious and life-threatening diseases. Abpro focuses on novel antibody construction in immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, Abpro is developing a next-generation antibody pipeline independently or through collaborations with global pharmaceutical and research institutions.
Company Financials
EPS
ABP has released its 2022 Q2 earnings. EPS was reported at -0.01, versus the expected 0.00, missing expectations. The chart below visualizes how ABP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
